EXPEDIENT LIQUID-CHROMATOGRAPHIC ASSAY FOR PACLITAXEL IN PLASMA AFTER ITS ADMINISTRATION TO CANCER-PATIENTS

被引:12
作者
ELYAZIGI, A [1 ]
YUSUF, A [1 ]
机构
[1] KING FAISAL SPECIALIST HOSP & RES CTR,DEPT BIOL & MED RES,PHARMACOKINET LAB,RIYADH 11211,SAUDI ARABIA
关键词
LIQUID CHROMATOGRAPHY; PACLITAXEL; PLASMA CONCENTRATIONS; PHARMACOKINETICS; CANCER PATIENTS;
D O I
10.1097/00007691-199510000-00012
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A rapid and expedient liquid chromatographic method for the analysis of paclitaxel in plasma is described. Paclitaxel and the internal standard (IS, N-nitrosodiphenylamine) were separated on a 10-mu m particle, 8 mm x 10 cm C-18 cartridge in conjunction with a radial compression system preceded by Guard Pak with a C-18 insert. The mobile phase was a mixture of 1 mM sodium phosphate buffer (pH 5) and acetonitrile (55.5:45.5 per volume), and the flow rate was 4.5 ml/min. The compounds were extracted from plasma with ethyl acetate and were detected in the effluent spectrophotometrically at 227 nm. The recovery of paclitaxel from plasma at concentrations equivalent to 50, 400, and 800 mu g/L paclitaxel in plasma was 79.1, 75.2, and 74.3%, respectively, and the retention times of the drug and IS under these conditions were 5.26 and 6.45 min, respectively. The relationship between the concentration and peak height ratio (drug/IS) was linear (r = 0.9938-0.9998) in the range of 10-1,600 mu g/L, and no interference in the assay was observed. The intrarun coefficient of variations (CV) at 50, 250, and 800 mu g/L were 4.9, 5.4, and 4.1%, respectively, and the deviations from theoretical accuracy at these concentrations were 1.2, 0.5, and 5.4%, respectively. We are currently using this assay to investigate the pharmacokinetics of paclitaxel in cancer patients treated with this agent in a combined chemotherapy.
引用
收藏
页码:511 / 515
页数:5
相关论文
共 14 条
[1]   ANALYSIS OF TAXOL AND RELATED DITERPENOIDS FROM CELL-CULTURES BY LIQUID-CHROMATOGRAPHY ELECTROSPRAY MASS-SPECTROMETRY [J].
BITSCH, F ;
MA, WW ;
MACDONALD, F ;
NIEDER, M ;
SHACKLETON, CHL .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1993, 615 (02) :273-280
[2]   HPLC SEPARATION OF TAXOL AND CEPHALOMANNINE [J].
CARDELLINA, JH .
JOURNAL OF LIQUID CHROMATOGRAPHY, 1991, 14 (04) :659-665
[3]  
GREGORY RE, 1993, CLIN PHARMACY, V12, P401
[4]  
GROTHAUS PG, 1982, CANCER TREAT REP, V66, P1381
[5]  
HAMEL E, 1982, CANCER TREAT REP, V66, P1381
[6]   SEPARATION OF TAXOL FROM RELATED TAXANES IN TAXUS-BREVIFOLIA EXTRACTS BY ISOCRATIC ELUTION REVERSED-PHASE MICROCOLUMN HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
HARVEY, SD ;
CAMPBELL, JA ;
KELSEY, RG ;
VANCE, NC .
JOURNAL OF CHROMATOGRAPHY, 1991, 587 (02) :300-305
[7]  
Jaziri M, 1991, J Pharm Belg, V46, P93
[8]  
LONGNECKER SM, 1987, CANCER TREAT REP, V71, P53
[9]   ANALYSIS OF ANTICANCER DRUGS IN BIOLOGICAL-FLUIDS - DETERMINATION OF TAXOL WITH APPLICATION TO CLINICAL PHARMACOKINETICS [J].
RIZZO, J ;
RILEY, C ;
VONHOFF, D ;
KUHN, J ;
PHILLIPS, J ;
BROWN, T .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1990, 8 (02) :159-164
[10]  
ROWINSKY EK, 1993, SEMIN ONCOL, V20, P16